Bristol Myers Squibb shared a post on LinkedIn:
“Today we reported our Q4 and full year 2025 earnings results, which reflect the strength of our Growth Portfolio and progress against our multi-year plan to position BMS for long-term growth. This momentum reinforces our foundation heading into a data rich 2026.
As we look ahead, we’re focused on delivering for patients and shareholders by advancing a truly differentiated pipeline and continuing to drive strong performance across the business.
Read more, including important cautionary statements about forward-looking information.”
Proceed to the video attached to the post.
More posts about Bristol Myers Squibb.